Impact of Estrogen Receptor β on Gene Networks Regulated by Estrogen Receptor α in Breast Cancer Cells

Two subtypes of the estrogen receptor (ER), ERalpha and ERbeta, mediate the actions of estrogens, and although 70% of human breast cancers express ERbeta along with ERalpha, little is known about the possible comodulatory effects of these two ERs. To investigate this, we have used adenoviral gene delivery to produce human breast cancer (MCF-7) cells expressing different levels of ERbeta, along with their endogenous ERalpha, and have examined the effects of ERbeta and receptor occupancy, using ER subtype selective ligands, on genome-wide gene expression by microarray and pathway network analysis. ERbeta had diverse effects on gene expression, enhancing or counteracting ERalpha regulation for distinct subsets of estrogen target genes. Strikingly, ERbeta in the absence of estradiol (E2), elicited the stimulation or suppression of many genes that were normally only regulated by ERalpha with E2. In addition, ERbeta plus E2 elicited the expression of a unique group of genes that were not regulated by ERalpha plus E2 alone. The expression of genes in many functional categories were modulated by ERbeta, with the greatest numbers associated with transcription factors and signal transduction pathways. Regulation of multiple components in the TGFbeta and semaphorin pathways, and of genes controlling cell cycle progression and apoptosis, may contribute to the suppression of cell proliferation observed with ERbeta. Our observations suggest that the relative levels of ERbeta and ERalpha in breast cancers are likely to impact cell proliferation and the activities of diverse signaling pathways and their response to ER ligands and endocrine therapies.

[1]  Zhiyuan Hu,et al.  Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  F. Bach,et al.  Bilirubin can induce tolerance to islet allografts. , 2006, Endocrinology.

[3]  Masakazu Toi,et al.  Clinical significance of estrogen receptor β in breast cancer , 2005, Cancer Chemotherapy and Pharmacology.

[4]  A. Chédotal,et al.  The brain within the tumor: new roles for axon guidance molecules in cancers , 2005, Cell Death and Differentiation.

[5]  Andy J. Minn,et al.  Genes that mediate breast cancer metastasis to lung , 2005, Nature.

[6]  Hans Clevers,et al.  FoxM1 is required for execution of the mitotic programme and chromosome stability , 2005, Nature Cell Biology.

[7]  M. Cronin,et al.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.

[8]  J. Minna,et al.  Semaphorin 3B (SEMA3B) induces apoptosis in lung and breast cancer, whereas VEGF165 antagonizes this effect. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[9]  M. Detmar,et al.  Expression of the type-1 repeats of thrombospondin-1 inhibits tumor growth through activation of transforming growth factor-beta. , 2004, The American journal of pathology.

[10]  Rafael A. Irizarry,et al.  A Model-Based Background Adjustment for Oligonucleotide Expression Arrays , 2004 .

[11]  Fabio Stossi,et al.  Transcriptional profiling of estrogen-regulated gene expression via estrogen receptor (ER) alpha or ERbeta in human osteosarcoma cells: distinct and common target genes for these receptors. , 2004, Endocrinology.

[12]  M. Nilsson,et al.  Identification of Tamoxifen-Induced Coregulator Interaction Surfaces within the Ligand-Binding Domain of Estrogen Receptors , 2004, Molecular and Cellular Biology.

[13]  V. Speirs,et al.  Oestrogen receptor β: what it means for patients with breast cancer , 2004 .

[14]  J. Hartman,et al.  Estrogen receptor β inhibits 17β-estradiol-stimulated proliferation of the breast cancer cell line T47D , 2004 .

[15]  J. Frasor,et al.  Therapeutic targeting in the estrogen receptor hormonal pathway. , 2004, Seminars in oncology.

[16]  G. Firestone,et al.  Estrogen Receptor β Inhibits Human Breast Cancer Cell Proliferation and Tumor Formation by Causing a G2 Cell Cycle Arrest , 2004, Cancer Research.

[17]  B. L. Riggs,et al.  Estrogen receptor isoform‐specific regulation of endogenous gene expression in human osteoblastic cell lines expressing either ERα or ERβ , 2003 .

[18]  Barry Komm,et al.  Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. , 2003, Endocrinology.

[19]  Douglas A. Hosack,et al.  Identifying biological themes within lists of genes with EASE , 2003, Genome Biology.

[20]  B. Katzenellenbogen,et al.  Activities of estrogen receptor alpha- and beta-selective ligands at diverse estrogen responsive gene sites mediating transactivation or transrepression , 2003, Molecular and Cellular Endocrinology.

[21]  M. Tessier-Lavigne,et al.  Class 3 semaphorins control vascular morphogenesis by inhibiting integrin function , 2003, Nature.

[22]  R. Kalluri,et al.  BMP-7 counteracts TGF-β1–induced epithelial-to-mesenchymal transition and reverses chronic renal injury , 2003, Nature Medicine.

[23]  C. Cordon-Cardo,et al.  A multigenic program mediating breast cancer metastasis to bone. , 2003, Cancer cell.

[24]  K. Korach,et al.  Stromal cell-derived factor 1, a novel target of estrogen receptor action, mediates the mitogenic effects of estradiol in ovarian and breast cancer cells. , 2003, Molecular endocrinology.

[25]  Carolyn L. Smith,et al.  Mechanistic Differences in the Activation of Estrogen Receptor-α (ERα)- and ERβ-dependent Gene Expression by cAMP Signaling Pathway(s)* , 2003, The Journal of Biological Chemistry.

[26]  Sreekanth H. Chalasani,et al.  A Chemokine, SDF-1, Reduces the Effectiveness of Multiple Axonal Repellents and Is Required for Normal Axon Pathfinding , 2003, The Journal of Neuroscience.

[27]  K. Dahlman-Wright,et al.  Estrogen Receptor (ER)-β Reduces ERα-Regulated Gene Transcription, Supporting a “Ying Yang” Relationship between ERα and ERβ in Mice , 2003 .

[28]  M. Low,et al.  Involvement of bone morphogenetic protein 4 (BMP-4) in pituitary prolactinoma pathogenesis through a Smad/estrogen receptor crosstalk , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[29]  H. Kiyokawa,et al.  The Forkhead Box m1b transcription factor is essential for hepatocyte DNA replication and mitosis during mouse liver regeneration , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[30]  Chris Albanese,et al.  Opposing Action of Estrogen Receptors α and β on Cyclin D1 Gene Expression* , 2002, The Journal of Biological Chemistry.

[31]  Tetsuya Yamamoto,et al.  Cross-talk between bone morphogenic proteins and estrogen receptor signaling. , 2002, Endocrinology.

[32]  Tianyi Mao,et al.  MICALs, a Family of Conserved Flavoprotein Oxidoreductases, Function in Plexin-Mediated Axonal Repulsion , 2002, Cell.

[33]  Steven C. Lawlor,et al.  GenMAPP, a new tool for viewing and analyzing microarray data on biological pathways , 2002, Nature Genetics.

[34]  K. Korach,et al.  Allosteric regulation of estrogen receptor structure, function, and coactivator recruitment by different estrogen response elements. , 2002, Molecular endocrinology.

[35]  Simak Ali,et al.  Endocrine-responsive breast cancer and strategies for combating resistance , 2002, Nature Reviews Cancer.

[36]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[37]  Christopher M. Gallo,et al.  TGIF2 Interacts with Histone Deacetylase 1 and Represses Transcription* , 2001, The Journal of Biological Chemistry.

[38]  B. Katzenellenbogen,et al.  Human estrogen receptor beta-specific monoclonal antibodies: characterization and use in studies of estrogen receptor beta protein expression in reproductive tissues , 2001, Molecular and Cellular Endocrinology.

[39]  J. Gustafsson,et al.  Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors. , 2001, Cancer research.

[40]  J. Thomsen,et al.  Mechanisms of estrogen action. , 2001, Physiological reviews.

[41]  B. Katzenellenbogen,et al.  Estrogen receptors: selective ligands, partners, and distinctive pharmacology. , 2000, Recent progress in hormone research.

[42]  B. Katzenellenbogen,et al.  Pyrazole ligands: structure-affinity/activity relationships and estrogen receptor-alpha-selective agonists. , 2000, Journal of medicinal chemistry.

[43]  B. Katzenellenbogen,et al.  Conformational Changes and Coactivator Recruitment by Novel Ligands for Estrogen Receptor-α and Estrogen Receptor-β: Correlations with Biological Character and Distinct Differences among SRC Coactivator Family Members. , 2000, Endocrinology.

[44]  J. Kurebayashi,et al.  Expression Levels of Estrogen Receptor-α, Estrogen Receptor-β, Coactivators, and Corepressors in Breast Cancer , 2000 .

[45]  K. Luo,et al.  Negative Feedback Regulation of TGF-β Signaling by the SnoN Oncoprotein , 1999 .

[46]  M. Poo,et al.  Plexins Are a Large Family of Receptors for Transmembrane, Secreted, and GPI-Anchored Semaphorins in Vertebrates , 1999, Cell.

[47]  B. Katzenellenbogen,et al.  Adenovirus-mediated delivery of a dominant negative estrogen receptor gene abrogates estrogen-stimulated gene expression and breast cancer cell proliferation. , 1999, Molecular endocrinology.

[48]  V. Giguère,et al.  Ligand-independent recruitment of SRC-1 to estrogen receptor beta through phosphorylation of activation function AF-1. , 1999, Molecular cell.

[49]  N. Kaminski,et al.  The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. , 1999, Cell.

[50]  B. Katzenellenbogen,et al.  Transcription Activation by the Human Estrogen Receptor Subtypeβ (ERβ) Studied with ERβ and ERα Receptor Chimeras* *This work was supported by NIH Grants CA-18119 and CA-60514 (to B.S.K.). , 1998, Endocrinology.

[51]  Alex L Kolodkin,et al.  Neuropilin Is a Semaphorin III Receptor , 1997, Cell.

[52]  B. Katzenellenbogen,et al.  Response-specific antiestrogen resistance in a newly characterized MCF-7 human breast cancer cell line resulting from long-term exposure to trans-hydroxytamoxifen , 1996, The Journal of Steroid Biochemistry and Molecular Biology.

[53]  J. Polman,et al.  ERβ: Identification and characterization of a novel human estrogen receptor , 1996 .

[54]  J. Gustafsson,et al.  Cloning of a novel receptor expressed in rat prostate and ovary. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[55]  R. Dickson,et al.  Growth factors in breast cancer. , 1995, Endocrine reviews.

[56]  R. Clarke,et al.  MCF7/LCC2: a 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780. , 1993, Cancer research.

[57]  B. Katzenellenbogen,et al.  Differential regulation of gene expression by estrogen in estrogen growth-independent and -dependent MCF-7 human breast cancer cell sublines. , 1991, Molecular endocrinology.

[58]  B. Katzenellenbogen,et al.  Phenol red in tissue culture media is a weak estrogen: implications concerning the study of estrogen-responsive cells in culture. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[59]  R. Janknecht,et al.  Transcriptional regulation of Smad2 is required for enhancement of TGFβ/Smad signaling by TGFβ inducible early gene , 2002 .

[60]  Yusuke Nakamura,et al.  Identification of semaphorin3B as a direct target of p53. , 2002, Neoplasia.

[61]  Susumu Goto,et al.  KEGG: Kyoto Encyclopedia of Genes and Genomes , 2000, Nucleic Acids Res..

[62]  B. Katzenellenbogen,et al.  Novel ligands that function as selective estrogens or antiestrogens for estrogen receptor-alpha or estrogen receptor-beta. , 1999, Endocrinology.

[63]  D. McDonnell,et al.  The Estrogen Receptor ␤-isoform (er␤) of the Human Estrogen Receptor Modulates Er␣ Transcriptional Activity and Is a Key Regulator of the Cellular Response to Estrogens and Antiestrogens* , 2022 .